For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | - | 2,820 | - | - |
| Research and development | 17,808 | 17,133 | 17,044 | 17,741 |
| General and administrative | 5,653 | 5,437 | 5,870 | 6,013 |
| Total costs and operating expenses | 23,461 | 22,570 | 22,914 | 23,754 |
| Loss from operations | -23,461 | -19,750 | -22,914 | -23,754 |
| Interest and investment income | 774 | 995 | 1,241 | 1,846 |
| Sublease income | 684 | 684 | 515 | 705 |
| Total other income, net | 1,458 | 1,679 | 1,756 | 2,551 |
| Loss before income taxes | -22,003 | -18,071 | - | - |
| Income tax expense | - | 283 | - | - |
| Net loss | -22,003 | -18,354 | -21,158 | -21,203 |
| Net unrealized gain (loss) on marketable debt securities | 74 | -54 | -121 | 453 |
| Other comprehensive gain (loss) | 74 | -54 | -121 | 453 |
| Comprehensive loss | -21,929 | -18,408 | -21,279 | -20,750 |
| Earnings per share, basic, total | -0.35 | -0.3 | -0.35 | -0.35 |
| Earnings per share, diluted, total | -0.35 | -0.3 | -0.35 | -0.35 |
| Weighted average number of shares outstanding, basic | 62,557,386 | 61,918,826 | 61,048,948 | 60,715,041 |
| Weighted average number of shares outstanding, diluted, total | 62,557,386 | 61,918,826 | 61,048,948 | 60,715,041 |
Pyxis Oncology, Inc. (PYXS)
Pyxis Oncology, Inc. (PYXS)